It's called the Vivo NEX, and it's actually available for purchase. To achieve this notch-less look, Vivo made several bold choices: It placed the selfie camera into a pop-up mechanism on top of ...

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Intellia's technology platform specializes in Clustered Regularly Interspaced Short ...

Dosed first patient in global Phase 3 HAELO study evaluating NTLA-2002 for hereditary angioedema (HAE)Expect to complete enrollment of the HAELO ...

Truist analyst Joon Lee lowered the firm’s price target on Intellia Therapeutics (NTLA) to $50 from $90 and keeps a Buy rating on the shares.

Intellia reports better-than-expected fourth-quarter 2024 results. The company provides updates on its pipeline candidates.

This transformative therapy would also be the first approved using in vivo CRISPR gene editing. Let's move on to nex-z in development for the treatment of ATTR amyloidosis. Starting with ATTR ...

and nexiguran ziclumeran (nex-z) for ATTR amyloidosis as it anticipates its first commercial launch in 2027. The discontinued programmes are headed by NTLA-3001, an in vivo CRISPR drug developed ...

While ex vivo therapies modify patients’ cells outside the body ... The goal is to focus all of the resources on NTLA-2002 for hereditary angioedema (HAE) and nex-z for transthyretin (ATTR) ...

Vivo is expected to hold a major launch event in April in China. The event is likely to see the arrival of multiple devices, ...

Vivo is gearing up to launch its next big flagship, the X200 Ultra. Expected to launch in China sometime between mid-to-late ...

Arguably the best photo processing of any midrange phone, the Vivo V50’s camera shines even if availability is limited on ...

Vivo V50 is to launch on February 17, check out the upgrades in comparison to last year’s Vivo V40 model. Vivo V50 vs Vivo V40: In just a few months, Vivo is launching its new generation V ...